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Abstract
Although administration of the vascular endothelial growth factor (VEGF), a potent angiogenic factor, could
improve the overall survival of destroyed sinusoidal endothelial cells (SEC) in chemically induced murine acute
hepatic failure (AHF), the mechanistic roles of the VEGF receptors have not been elucidated yet. The respective
roles of VEGF receptors; namely, Flt-1 (VEGFR-1: R1) and KDR/Flk-1 (VEGFR-2: R2), in the D-galactosamine (Gal-N)
and lipopolysaccharide (LPS)-induced AHF were elucidated with specific neutralizing monoclonal antibody against
R1 and R2 (R1-mAb and R2-mAb, respectively). The serum ALT elevation, with a peak at 24 h after Gal-N+LPS intox-
ication, was markedly augmented by means of the R1-mAb and R2-mAb. The aggregative effect of R2-mAb was
more potent than that of R1-mAb, and the survival rate was 70% in the R2-mAb-treated group and 100% in the
other groups. The results of SEC destruction were almost parallel to those of the ALT changes. Our in-vitro study
showed that R1-mAb and R2-mAb significantly worsened the Gal-N+LPS-induced cytotoxicity and apoptosis of SEC
mediated by caspase-3, which were almost of similar magnitude to those in the in-vivo study. In conclusion, these
results indicated that R2 is a major regulator of the salvage effect of VEGF on the maintenance of SEC architecture
and the anti-apoptotic effects against chemically-induced murine AHF.
Background
Despite the recent advances in liver support systems,
acute hepatic failure (AHF) still has a high mortality
rate [1]. Among several types of non-parenchymal
cells, the sinusoidal endothelial cells (SEC) are consid-
ered the most important in the recovery from AHF [2].
The initial wave of hepatocyte proliferation is followed
by SEC proliferation and penetration of avascular
hepatocellular islands leading to formation of new
sinusoids [3]. Several studies have proven that neo-
vascularization requires these processes during the
recovery from AHF [4].
Angiogenesis is the development of new vasculature
from the pre-existing blood vessels and/or the circulat-
ing EC stem cells [5,6]. Emerging evidences have shown
that angiogenesis plays a pivotal role in many physiolo-
gical and pathological processes, such as tumor growth,
arthritis, psoriasis, and diabetic retinopathy [5,7]. Angio-
genesis is regulated by the net balance between pro-
angiogenic factors and angiogenic inhibitors. To date,
many positive and negative angiogenic-modulating fac-
tors have been identified. Among these, the vascular
endothelial growth factor (VEGF) is the most potent fac-
tor in the angiogenesis process [8]. Emerging evidences
have shown that VEGF plays a pivotal role in many pro-
cesses of physiological and pathological angiogenesis [9].
VEGF is not only an angiogenic factor but also known
as a survival factor for EC [10]. Regarding liver regen-
eration, it has been shown that the VEGF expression
increased markedly during liver regeneration induced
either by partial hepatectomy (PH) or drug intoxication
[11]. Furthermore, exogenous VEGF administration after
PH promoted the proliferative activity in the liver [12].
Conversely, it has shown that neutralization of VEGF
significantly inhibited the proliferative activity in the
liver during regeneration after PH [13]. In addition to
the vitality of regeneration, we previously reported that
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the VEGF-mediated maintenance of the SEC architec-
ture through anti-apoptotic effects in AHF is important.
VEGF treatment significantly reduced the mortality rate
of AHF in the rat through maintenance of the SEC
architecture and anti-apoptotic effect on SEC [14].
The biological effects of VEGF are mediated by two
receptor tyrosine kinases; namely, Flt-1 (VEGFR-1: R1)
and KDR/Flk-1 (VEGFR-2: R2), which differ consider-
ably in the signaling properties [15]. Both VEGFRs are
expressed almost exclusively on the surface of EC. R1
activation resulted in paracrine release of the hepatocyte
growth factor (HGF), interleukin-6 (IL-6), and other
hepatotrophic molecules from SEC, and the hepatocytes
were stimulated to proliferate when cultured with SEC
[16]. R2 activation led to an increase in proliferation of
EC after hepatic injury, that in turn, led to EC regenera-
tion. It has already been shown that neutralization of
VEGF with anti-VEGF antibody significantly inhibited
the proliferative activity in liver regeneration after PH
[13]. And that the specific neutralizing monoclonal anti-
body against R2 (R2-mAb) would impair liver regenera-
tion in mice [17]. Using R-2mAb, we previously found
that R2 was a major regulator of VEGF-mediated tumor
development and angiogenesis in several animal models
[18,19]. However, the respective roles of the VEGF
receptors in AHF have not been elucidated yet.
In the current study, we elucidated the respective roles
of R1 and R2 in the Gal-N+LPS-induced AHF using
specific neutralizing monoclonal antibody for R1 and
R2, especially in conjunction with maintenance of the
SEC structure.
Methods
Reagents and animal treatment
Ten-week-old male Balb/c mice weighing (18-20 g)
obtained from Japan SLC Inc (Hamamatsu, Shizuoka,
Japan) were used. They were housed in stainless steel,
mesh cages under controlled conditions of temperature
(23 ± 3°C) and relative humidity (50 ± 20%), with 10-15
air changes per hour and light illumination for 12 hours
(h) a day. The animals were allowed access to food and
tap water ad libitum throughout the acclimatization and
experimental periods. D-galactosamine hydrochloride
(Gal-N) was purchased from Nacalai Tesque (Kyoto,
Japan) and Escherichia coli endotoxin (LPS, serotype 055:
B5) was purchased from Sigma Chemical (St. Louis, MO,
USA). The anti-R1 and anti-R2 specific neutralizing
monoclonal antibodies (R1-mAb and R2-mAb, respec-
tively) were generated as described previously [20]. Briefly,
hybridoma cells were grown via continuous feed fermenta-
tion in a serum-free medium. mAbs were purified from
conditioned media by a multistep chromatography process
and assessed for purity in SDS-PAGE, and the immuno-
reactivity with soluble R-1 and R-2 receptors was checked
by ELISA. The negative control polyclonal rat IgG was
purchased from Jackson ImmunoResearch Laboratories
(West Grove, PA, USA). mAbs and control rat IgG were
tested for endotoxin using the Pyrogent Plus Limulus
amebocyte lysate kit (BioWhittaker, Walkersville, MD,
USA). All antibody preparations used in animal studies
contained ≤1.25 endotoxin units/ml of endotoxin. It has
been shown that R2-mAb exerted a VEGFR2 inhibitory
effect in a dose-dependent manner, and that the maximal
effect was achieved at a dose of 800 μg/mouse adminis-
tered twice a week [21,22]. We therefore employed this
dose in the current study. The mice were randomly
divided into four groups. Group 1 (G1) consisted of the
phosphate buffer saline (PBS) and the control immuno-
globulin-G (IgG)-treated mice and served as a control
group. The other mice were injected with Gal-N (375 mg/
kg) and LPS (50 μg/kg) intraperitoneally. Since the survival
rate by combination treatment with 500 mg/kg of Gal-N
and LPS (50 μg/kg) was 27% [14,23], we decreased the
dose of Gal-N in the current study to induce a moderate
liver injury. Mice in group 2 (G2) received the control IgG
at 0 h. Animals in group 3 (G3) and group 4 (G4) received
equal amounts of R1mAb or R2mAb intraperitoneally at 0
h, respectively. Liver injury was evaluated by measuring
the serum alanine aminotransferase (ALT), which reaches
a peak at 24 h [14,23]. Fifteen mice from each experimen-
tal group were used for monitoring the survival rate
chronologically. Ten mice from each group were killed at
24 h under anesthesia. Another experiment was performed
to investigate the survival rate (n = 10, each group). Blood
samples were withdrawn via the abdominal aorta. All ani-
mal procedures were performed according to approved
protocols and in accordance with the standard recommen-
dations for the proper care and use of laboratory animals.
Immunohistochemistry
To elucidate the effects of mAbs on the maintenance of
SEC structure at 24 h after administration of Gal-
N+LPS, an immunohistochemical analysis of ICAM-1
was performed as described previously [24]. The livers
from five mice in each group were carefully excised at
24 h after intoxication. Then, 5-μm thick slices from the
major liver lobes were fixed in ice-cold acetone and
embedded in paraffin. Serial sections were prepared
from each fixed liver. The first was routinely stained
with hematoxylin and eosin for histological examination.
The other sections were used for immunohistochemical
analysis. The immunopositive SEC were evaluated with
Adobe Photoshop and NIH image software as previously
described [25].
In-vitro cytotoxicity and apoptosis of EC
The in-vitro cytotoxicity of EC treated with Gal-N
(20 mM) and LPS (100 mg/ml) was determined by
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MTT assay, which reflected the mitochondrial activity as
described elsewhere (n = 6 per group) [26]. The effects
of mAbs treatment on the EC apoptosis were examined
by the Cell Death Detection ELISA kit (Roche, Tokyo,
Japan) according to the manufacturer’s instructions as
described previously [27]. We also examined the activity
of caspase-3 which is apoptosis regulatory protein by
Caspase-3/CPP32 Colorimetric Assay Kit (BioVision
Research Products, CA, USA) according to the manufac-
turer’s instructions.
Statistical analysis
The data are presented as means ± SD. The statistical
significance of differences was evaluated by one-way
analysis of variance followed by Barlett’s test for com-
parisons among four or eight means. A p value of <0.05
was considered statistically significant.
Results
Effects of VEGFR-mAbs on the serum ALT and survival
rate
The effects of the mAbs treatment on the Gal-N+LPS-
induced ALT elevation and survival rate in AHF were
first examined. As shown in Fig. 1A, the serum ALT
levels in the mAbs-treated groups were markedly higher
than in the Gal-N-treated group at 24 h after Gal-
N+LPS intoxication. The ALT level with R2-mAb was
significantly higher than with R1-mAb. We also
examined the survival rate at 24 h after intoxication in
relation to the peak of ALT as described previously
[14,23]. In the control (G1), the Gal-N-treated (G2), and
R1-mAb-treated (G3) groups, all animals survived. On
the other hand, the survival rate in the R2mAb-treated
animals (G4) was 70% (Fig. 1B). No mice died after 24 h
in all groups.
Effects of VEGFR-mAbs on the maintenance of SEC
architecture
We next examined the effects of R1-mAb and R2-mAb
on the maintenance of SEC architecture after intoxica-
tion by combination of Gal-N+LPS. We previously
observed that the initial SEC construction in the
untreated group was almost obliterated at 24 h after
intoxication [14,23]. In this study, we elucidated the
effects of mAbs at 24 h. The R1-mAb and R2-mAb
treatment significantly augmented the destruction of the
SEC architecture in the liver after Gal-N+LPS intoxica-
tion (Fig. 2A). Similar to the ALT level, the destruction
magnitude with R2-mAb treatment was significantly
higher than that with R-1 mAb. Semiquantitative analy-
sis of the IACM-1-positive vessels confirmed these
results (Fig. 2B). We examined the mRNA expression of
ICAM-1, and observed that the mRNA expression of
ICAM-1 was almost similar to that of the immunohisto-
chemical analysis. Moreover, we also investigated tyro-
sine-phosphorylated VEGFR-1 and VEGFR-2 in the liver
Figure 1 The effects of R1-mAb and R2-mAb on the serum ALT level and survival rate of rats with Gal-N+LPS-induced acute hepatic
failure. A: The effects of R1-mAb and R2-mAb on the serum ALT level following Gal-N+LPS intoxication. Injection of Gal-N+LPS resulted in a
moderate increase of the serum ALT level at 24 h. Both R1-mAb and R2-mAb significantly augmented the elevation of ALT, and the elevation
magnitude with R2-mAb was significantly higher than with R1-mAb. B: The survival rate 24 h after intoxication in relation to the peak of ALT.
The survival rate in the R2mAb-treated animals was 70%, whereas no animals died in the other groups. No mice died after 24 h in all groups.
Cont: Control IgG-treated mice (G1). Mice in group 2 (G2: Gal-N) simultaneously received Gal-N (375 mg/kg), LPS (50 μg/kg), and the control IgG
intraperitoneally at 0 h. Instead of the control IgG, animals in group 3 (G3: R1) and group 4 (G4: R2) received the equal amounts of R1mAb or
R2mAb intraperitoneally at 0 h, respectively. Each points in Fig. 1A represents the mean ± SD. *: Statistically significant differences between the
experimental groups (p < 0.05).
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after i.p. injection of R-1mAb and R-2mAb. We con-
firmed that the R-1mAb and R-2mAb significantly
inhibited tyrosine-phosphorylation of the respective
receptors (data not shown).
In-vitro studies
A set of in-vitro experiment was performed to assess the
effects of mAbs on cytotoxicity and apoptosis induced
by Gal-N+LPS. As shown in Fig. 3, the R1-mAb and
R2-mAb treatment significantly augmented the cytotoxi-
city of EC. Moreover, the effect of R2-mAb was much
more potent than that of R1-mAb. We also elucidated
the effects on the apoptosis. Similar to the results of
cytotoxicity, R1-mAb and R2-mAb treatment signifi-
cantly increased the apoptotic index induced by Gal-N
+LPS. The effect of R2-mAb on the apoptotic index was
also more potent than that of R1-mAb (Fig. 4A). To
examine the possible signaling cascade of apoptosis, we
measured the caspase-3 activity, which is known as one
of the apoptosis-regulatory key proteins, by colorimetric
assay. The effects of mAbs on the caspase-3 were almost
in parallel with the augmentation of the apoptotic index,
indicating that the apoptosis signaling induced by
Figure 2 The effects of R1-mAb and R2-mAb on the maintenance of EC structure of rats with Gal-N+LPS-induced acute hepatic failure.
A: Representative features of the effects of R1-mAb and R2-mAb on maintenance of the SEC structure after intoxication by combination of Gal-N
+LPS. The R1-mAb and R2-mAb treatment significantly augmented the destruction of the SEC architecture in the liver after Gal-N+LPS
intoxication. The SEC architecture was evaluated by the ICAM-1-immunopositive vessels. Original magnification: × 40. B: Semi-quantitative
analysis of the SEC architecture in the liver following the Gal-N+LPS intoxication. Individual treatment with R1-mAb and R-2mAb significantly
augmented the destruction of the SEC architecture in the liver both at 24 h after intoxication. The destruction magnitude of R2-mAb was
significantly higher than that of R-1 mAb. Cont: Control IgG-treated mice (G1). Mice in group 2 (G2: Gal-N) simultaneously received Gal-N (375
mg/kg), LPS (50 μg/kg), and the control IgG intraperitoneally at 0 h. Instead of the control IgG, animals in group 3 (G3: R1) and group 4 (G4: R2)
received equal amounts of R1mAb or R2mAb intraperitoneally at 0 h, respectively. MV: microvessel. The data represent the mean ± SD. *:
Statistically significant differences between the experimental groups (p < 0.05).
Figure 3 Effects of R1-mAb and R2-mAb on the in-vitro Gal-N
+LPS-induced cytotoxicity of EC. The cell cytotoxicity was
measured by the MTT assay as described in the Materials and
Methods. The R1-mAb and R2-mAb treatment significantly
augmented the cytotoxicity of EC. Moreover, the effect of R2-mAb
was much more potent than that of R1-mAb. Cont: Control IgG-
treated group. R1 and R2: R1-mAb- and R2-mAb-treated group,
respectively. The data represent the mean ± SD. *: Statistically
significant differences between the experimental groups (p < 0.05).
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R1-mAb and R2-mAb was mainly mediated by the
caspase-3 cascade (Fig. 4B).
Discussion
Angiogenesis is a complex and critical process in the
development, growth, wound healing, and regeneration.
Recent studies have revealed that these processes com-
monly occur together in many disease states, where neo-
vascularization is believed to initiate the pathological
cascade [28]. Among the identified angiogenic factors to
date, VEGF is one of the most potent and central factors
in many physiological and pathological processes
[15,29,30]. VEGF is now recognized as a survival factor
for EC as well as a major regulator of angiogenesis. We
previously reported that recombinant VEGF administra-
tion markedly reduced the mortality rate of AHF in the
rat through maintenance of the SEC architecture, by
attenuating cytotoxicity and apoptosis of EC [23].
The biological activities of VEGF are mediated mainly
via two type III tyrosine kinase receptors; namely, R1
and R2, which serve different roles in the angiogenesis
and signal transduction pathways [15,29,31,32].
Although R1 shows a high affinity to VEGF, at least 10-
fold higher than R2, R2 is a major positive mitogenic
signal transducer through its strong kinase activity as
compared with R1 [9]. Overexpression of R2 in the por-
cine EC led to actin reorganization, chemotaxis, and
mitogenesis in response to VEGF, though R1 expression
in the same cells had a minimal effect in vitro [31].
However, recent studies have revealed that R1 was also
involved in the pathological angiogenesis, such as tumor
growth [22,33-36]. In the present study, we found that
either inhibition of R1 or R2 significantly augmented the
SEC destruction, and that treatment with R2-mAb was
more potent than that with R1-mAb. Furthermore, only
R-2mAb treatment was lethal but not R1-mAb in the
Gal-N+LPS-induced murine AHF. These results indi-
cated that VEGF-VEGFR interaction was a major regula-
tor in the maintenance of the SEC architecture in Gal-
N+LPS-induced AHF.
It would be an important issue to elucidate the locali-
zation of R1-mAb and R2-mAb during this process. It
is, however, difficult to make marking on these mAbs
for immunohistochemical analysis at this time. We tried
a couple of times to localize R1 and R2 by immunohis-
tochemical double-staining with ICAM-1, but we could
not get good results. The background was very intense,
and the interpretation was very difficult (data not
shown). We previously utilized SE-1 as a marker of
SEC, as SE-1 is reportedly a specific marker of the liver
SEC [37]. However, we could not apply SE-1 in the cur-
rent study, because this antibody was only specific for
the rat but not the mouse. We could not obtain any
specific R1-mAb and R2-mAb for the rat at this time.
When the mAbs against the rat R1 and R2 become
available, further studies would be required with these
Figure 4 Effects of R1-mAb and R2-mAb on the in-vitro apoptosis and caspase-3 activity of EC. A: The R1-mAb and R2-mAb significantly
increased the apoptotic index induced by Gal-N+LPS. The effect of R2-mAb on the apoptotic index was also more potent than R1-mAb. The
effects of mAbs on the caspase-3 were almost in parallel with the augmentation of the apoptotic index (B). Cont: Control IgG-treated group.
R1and R2: R1-mAb- and R2-mAb-treated group, respectively. The data represents the mean ± SD (n = 6). *: Statistically significant differences
between the experimental groups (p < 0.05).
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mAbs and SE-1 to elucidate the localization of respec-
tive receptors in AHF.
Regarding the salvage effect of VEGF against AHF,
inhibition of apoptosis in EC was also a prerequisite
[23]. There is now a consensus that R2 is the major
mediator of the anti-apoptotic as well as the mitogenic
effects of VEGF. R2 and PI3-kinase/Akt signal transduc-
tion pathway as a crucial element in the processes lead-
ing to endothelial cell survival induced by VEGF [38].
Recent studies on R1 have also detected a pro-survival
signal in ECs, possibly mediated by induction of the
anti-apoptotic gene that survives under some circum-
stances [9]. Furthermore, it has been reported that the
transplanted EPC secreted growth factor in a paracrine
manner and inhibited cell apoptosis through R1 and R2.
Similar to the in-vivo studies, we found that inhibition
of either R1-mAb or R2-mAb significantly augmented
the apoptosis. In addition, treatment with R2-mAb was
more potent than that with R1-mAb, indicating that
VEGF-R2 interaction was a major regulator of the anti-
apoptotic effect as well as the maintenance of the SEC
architecture. Concerning the apoptotic signaling, it has
been reported that there is differential involvement of
Akt and Erk1/2 in apoptosis and proliferation signal
transduction between R1 and R2 [39]. Although we
found that the caspase-3 activity was almost similar to
that of the total apoptotic index, further studies are
required utilizing selective signal pathway inhibitors to
determine the downstream nuclear protein.
Since the impaired liver regeneration is one of the
most critical issues in the prognosis, VEGF is considered
to play an important role in hepatic regeneration via
maintenance of the SEC architecture, attenuating cyto-
toxicity and anti-apoptosis for EC. It has been reported
that the cross-talk between SEC and hepatocytes played
a critical role in liver regeneration following toxic injury
[3]. The increased expressions of VEGF and VEGFR
correlated with the rate of SEC proliferation after PH
[40]. R2 is a major positive mitogenic signal transducer
through its strong kinase activity as compared with R1
[9]. R2 activation not only mediated SEC proliferation
but also resulted in induction of a subset of hepato-
trophic genes [41]. It has been shown that R1 is also an
important mediator in bone marrow-derived EC pro-
genitor cell recruitment [22], and this type of cells
reportedly contributes to liver regeneration [13]. More-
over, it has been reported that the VEGF-mediated para-
crine effect on SEC through R2 was involved in
maintenance of the SEC phenotype [42]. These co-ordi-
nate effects by VEGF and VEGFR interaction should
contribute to decrease the overall survival of the R2-
mAb-treated group with AHF in the current study.
In conclusion, we observed that VEGF-VEGFRs inter-
action was a prerequisite against chemically-induced
murine AHF, and that R2 was a major regulator of
maintenance of the SEC architecture by attenuating the
cytotoxicity and apoptosis of EC more than R1. In addi-
tion to VEGF administration, stimulation of VEGFRs,
especially R2, such as during gene delivery, would be an
alternative new therapeutic strategy for AHF in the
future.
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